Provided by Tiger Trade Technology Pte. Ltd.

Nurix Therapeutics

22.25
-0.4800-2.11%
Volume:952.18K
Turnover:20.83M
Market Cap:2.30B
PE:-6.52
High:22.60
Open:22.49
Low:21.55
Close:22.73
52wk High:28.23
52wk Low:9.00
Shares:103.41M
Float Shares:74.11M
Volume Ratio:1.16
T/O Rate:1.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4102
EPS(LYR):-3.0514
ROE:-80.30%
ROA:-40.06%
PB:5.71
PE(LYR):-7.29

Loading ...

Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says

MT Newswires Live
·
Aug 11

Nurix Therapeutics is Maintained at Outperform by RBC Capital

Dow Jones
·
Aug 11

RBC Adjusts PT on Nurix Therapeutics to $36 From $33, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
Aug 10

How Investors May Respond To Nurix Therapeutics (NRIX) Advancing Bexobrutideg Into Registrational Phase 3 With Roche

Simply Wall St.
·
Aug 06

Nurix CSO Gwenn Hansen Sells 4,111 Shares for $100,068.32

Reuters
·
Aug 05

Nurix Therapeutics Price Target Maintained with a $34.00/Share by Needham

Dow Jones
·
Aug 04

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a Stat6 Degrader

THOMSON REUTERS
·
Aug 04

Nurix Therapeutics - Has Received About $139 Mln Under 2019 Sanofi Collaboration

THOMSON REUTERS
·
Aug 04

Nurix Therapeutics - Eligible for About $453 Mln in Future Stat6 Milestones and Potential Royalties

THOMSON REUTERS
·
Aug 04

Nurix Therapeutics Enrolls First Patient in Phase 3 Blood Cancer Trial

MT Newswires Live
·
Aug 04

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 Daybreak Cll-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

THOMSON REUTERS
·
Aug 04

Nurix Therapeutics Chief Legal Officer Christine Ring Disposes of 16,589 Common Shares Worth $382,324.26

Reuters
·
Aug 04

Nurix Therapeutics is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Jul 29

Nurix Therapeutics is Maintained at Buy by UBS

Dow Jones
·
Jul 23

UBS Lifts Nurix Therapeutics Price Target to $31 From $23, Maintains Buy Rating

MT Newswires Live
·
Jul 22

Nurix Therapeutics, Roche Partner to Co-develop BTK Degrader Bexobrutideg in Deal Worth up to $2.3 Billion

Reuters
·
Jul 22

Nurix Therapeutics Announces Hsr Clearance of Global Collaboration with Roche to Co-develop and Co-commercialize Potential Best-in-class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

THOMSON REUTERS
·
Jul 22

Nurix Therapeutics - Co and Roche to Jointly Advance Bexobrutideg in Cll, B-cell Malignancies, MS, and Csu

THOMSON REUTERS
·
Jul 22

Nurix Therapeutics - to Receive $700 Mln Upfront, up to $2.30 Bln in Total Potential Payments

THOMSON REUTERS
·
Jul 22

Nurix Therapeutics - Development Costs Shared 40% Nurix, 60% Roche; U.S. Profits and Losses Split Equally

THOMSON REUTERS
·
Jul 22